AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

Shots:

  • The approval follows PR designation and is based on P-III KRONOS study assessing budesonide/glycopyrronium/formoterol fumarate vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate, demonstrated significant improvement in FEV1
  • The approval marks the first NMPA approval for a fixed-dose triple-combination regimen in a pressurized metered-dose inhaler device which utilizes Aerosphere delivery technology
  • Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US & EU. The triple combination regimen is k/a PT010 outside of China

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Times